Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Accured Expenses (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Change in Accured Expenses for 10 consecutive years, with $412000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 94.11% year-over-year to $412000.0, compared with a TTM value of -$15.6 million through Dec 2025, down 333.21%, and an annual FY2025 reading of -$15.6 million, down 333.21% over the prior year.
  • Change in Accured Expenses was $412000.0 for Q4 2025 at Zevra Therapeutics, up from -$4.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.0 million in Q4 2024 and bottomed at -$7.3 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$301850.0, with a median of -$35500.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 410.58% in 2021, then soared 889.3% in 2023.
  • Year by year, Change in Accured Expenses stood at $778000.0 in 2021, then soared by 140.23% to $1.9 million in 2022, then skyrocketed by 206.58% to $5.7 million in 2023, then rose by 22.02% to $7.0 million in 2024, then tumbled by 94.11% to $412000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ZVRA at $412000.0 in Q4 2025, -$4.7 million in Q3 2025, and -$4.0 million in Q2 2025.